Latest news about Themis Medicare
Themis Medicare
108.57
-0.14(-0.13%)
Company Performance:
View Company Insights1D-0.13%
1M-17.86%
6M+32.68%
1Y-12.49%
5Y+13.61%
More news about Themis Medicare
13Aug 26
Themis Medicare Q1 Results: Net Loss Narrows to ₹569 Million
Themis Medicare’s Q1 results show a consolidated net loss of ₹569 million, improving from ₹139 million in the prior year. The EBITDA loss widened to ₹524 million from ₹101 million. The company benefited from a ₹929 million profit on the sale of shares, which offset operational losses.
05Aug 26
Vividhmargi Trust pledges 2.53 crore Themis Medicare shares for debt security
Vividhmargi Trust has pledged 2.53 crore shares of Themis Medicare, representing 27.49% of the company's equity, to CTL Trusteeship Limited. This encumbrance serves as security for debentures issued by OSS Software Solutions Labs Private Limited, bringing the total pledged stake held by the trustee to 30.75%.
21Jul 26
Vividhmargi Trust pledges 27.49% stake in Themis Medicare
Vividhmargi Trust pledged 2,53,17,620 equity shares, representing 27.49% of Themis Medicare Limited, on June 29, 2026. The pledge was made in favor of CTL Trusteeship Limited for a loan amount of ₹135,00,00,000, to be used for personal purposes by the promoters. The disclosure was made to the stock exchanges on July 3, 2026.
04Jul 26
Vividhmargi Trust pledges 27.49% stake in Themis Medicare
Vividhmargi Trust pledged 2,53,17,620 shares, or 27.49%, of Themis Medicare Ltd to CTL Trusteeship Ltd on June 29, 2026. The pledge secures ₹135 crore of unrated debentures issued by OSS Software Solutions Labs for personal use by promoters.
29May 26
Themis Medicare Returns to Profit in FY26, Recommends Dividend of Re. 0.50 Per Share
Themis Medicare Limited returned to consolidated profitability in FY26 with a net profit of ₹1.14 crore, while Q4 FY26 saw a sharp turnaround with PAT of ₹8.89 crore and revenue rising 6.7% YoY to ₹76.53 crore. The Board recommended a final dividend of Re. 0.50 per share and re-appointed M/s. R. Nanabhoy & Co. as Cost Auditor for FY2026-27, with statutory auditors issuing an unmodified opinion on all financial results.
13May 26
Themis Medicare Submits Valuation Report and Compliance Certificate for Preferential Allotment of Convertible Warrants
Themis Medicare Limited filed a regulatory disclosure with BSE and NSE on 12th May, 2026, submitting a Valuation Report from an Independent Registered Valuer and an updated Compliance Certificate from a Practicing Company Secretary in connection with its proposed preferential allotment of convertible warrants. The process was initiated after board approval on 13th February, 2026, and the documents were hosted on the company's official website in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
09Apr 26
Themis Medicare Opens Special Window for Physical Share Transfer and Dematerialization
Themis Medicare Limited has opened a special one-year window from February 05, 2026 to February 04, 2027 for shareholders to re-lodge transfer requests and dematerialize physical shares, following SEBI Circular dated January 30, 2026. The facility targets shareholders who had transactions prior to April 01, 2019 but faced transfer process challenges, with transferred shares subject to mandatory Demat mode and one-year lock-in period.
28Mar 26
Themis Medicare Limited Announces Postal Ballot Results with All Four Resolutions Approved
Themis Medicare Limited announced the successful completion of its postal ballot process with all four proposed resolutions receiving overwhelming shareholder approval. The voting covered material related party transactions with various entities and the issuance of convertible warrants to Vividhmargi Investments Private Limited on a preferential basis.
28Mar 26
Vividhmargi Investments Increases Stake in Themis Medicare to 26.52% Through Amalgamation
Vividhmargi Investments Private Limited has acquired additional equity shares in Themis Medicare Limited through an approved amalgamation scheme, consolidating promoter group holdings. The transaction increased VMIPL's shareholding from 15.77% to 26.52%, with regulatory disclosures filed under SEBI Takeover Regulations on March 27, 2026.
27Mar 26
Themis Medicare receives tax demand notice of ₹13.32 crore from Income Tax Department
Themis Medicare Limited disclosed receiving a tax demand notice of approximately ₹13.32 crore from the Income Tax Department for assessment years 2017-18, 2018-19, and 2020-21. The largest component is ₹8.71 crore for AY 2017-18, followed by ₹4.17 crore for AY 2018-19, and ₹0.44 crore for AY 2020-21. The company plans to file an appeal and believes it has strong grounds to defend the matter, stating no adverse impact on its financial position or operations.
11Mar 26
Themis Medicare Committee Formally Approves Warrant Price Revision to Rs. 102.87
Themis Medicare Limited's Preferential Issue Committee has formally approved the revised pricing for convertible equity warrants at Rs. 102.87 per warrant during its March 10, 2026 meeting. The committee adopted a modified pricing certificate and approved the corrigendum to the February 25, 2026 postal ballot notice, following NSE observations. The warrants are being issued to Vividhmargi Investments Private Limited on a preferential basis, representing up to 4.99% of total shareholding equivalent to 45,95,795 equity shares, subject to shareholder and stock exchange approvals.
25Feb 26
Themis Medicare Approves Preferential Issue of 45,95,795 Convertible Equity Warrants at Rs. 100 Each
Themis Medicare Limited's Preferential Issue Committee approved the allotment of 45,95,795 convertible equity warrants to Vividhmargi Investments Private Limited at Rs. 100 per warrant on February 25, 2026. The issue price was rounded up from the minimum price of Rs. 99.76 as certified by practicing company secretary Mr. Abhishek Wagh. The company has scheduled a postal ballot from February 26 to March 27, 2026, to obtain shareholder approval for this preferential issue, which also requires stock exchange approval.
14Feb 26
Themis Medicare Limited Announces Resignation of Company Secretary and Compliance Officer
Themis Medicare Limited announced the resignation of Mr. Pradeep M. Chandan from his roles as Company Secretary, Compliance Officer, and Key Managerial Personnel, effective February 13, 2026. The resignation was attributed to other professional commitments, and the company has duly informed BSE and NSE about this management change under Regulation 30 compliance requirements.
11Dec 25
Themis Medicare Allots 60,000 Equity Shares Under Employee Stock Option Scheme
Themis Medicare Limited allotted 60,000 equity shares under its Employee Stock Option Scheme 2012 on December 11, 2025, following approval by the Allotment Committee. The shares, with a face value of ₹1.00 each, were issued to eligible employees upon exercise of vested options. This allotment increased the company's paid-up equity share capital from 9,20,40,120 to 9,21,00,120 shares. The newly issued shares rank pari-passu with existing equity shares and the company has completed all required regulatory disclosures with BSE and NSE.
13Nov 25
Themis Medicare Reports Loss in Q2 FY2026, Withdraws Merger with Gujarat Themis Biosyn
Themis Medicare Limited reported a net loss of Rs. 635.55 lakhs in Q2 FY2026, compared to a profit of Rs. 1,337.25 lakhs in Q2 FY2025. Revenue from operations decreased to Rs. 7,799.41 lakhs from Rs. 11,700.99 lakhs. The company withdrew from a proposed merger with Gujarat Themis Biosyn Limited and received approval to strike off its UK subsidiary, Carpo Medicals Limited. Themis Medicare will focus on its domestic pharmaceutical formulations business.
12Sept 25
Themis Medicare Declares Dividend, Appoints New Independent Director and Secretarial Auditor
Themis Medicare announced key decisions at its 55th AGM. The company declared a dividend of Rs 0.50 per share, appointed Ms. Neha Thakore as an Independent Woman Director for a five-year term, and selected M/s. SAV & Associates LLP as Secretarial Auditor. Shareholders approved financial statements, re-appointed Dr. Adam Demeter as director, ratified Cost Auditor remuneration, and approved commission for Non-Executive Directors.
04Aug 25
Themis Medicare Reports Q1 Net Loss of 142 Million Rupees Amid Revenue Decline
Themis Medicare, a pharmaceutical company, reported a consolidated net loss of ₹142.00 million in Q1, contrasting with a ₹247.00 million profit in the same quarter last year. Revenue decreased by 24.92% to ₹976.00 million from ₹1,300.00 million. EBITDA turned negative at ₹101.00 million loss, compared to a positive ₹292.00 million in the previous year's quarter.
20May 25
Themis Medicare Reports Q4 Revenue Decline and Net Loss
Themis Medicare's Q4 financial results show a significant downturn. The company reported a net loss of ₹96.60 million, contrasting with a profit of ₹66.40 million in the same quarter last year. Revenue decreased by 26.70% compared to the previous quarter. This marks a notable shift from the ₹5.20 million profit in the preceding quarter, indicating volatility in the company's financial performance.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Laurus Labs
Cipla
Dr Reddys Laboratories
Mankind Pharma
Aurobindo Pharma
Lupin
1,760.00
(+0.01%)
9,340.00
(-0.22%)
4,656.90
(+0.86%)
1,117.50
(+0.49%)
2,036.60
(+1.94%)
1,301.00
(-0.44%)
1,197.00
(+1.44%)
2,368.50
(-0.48%)
1,693.00
(+2.92%)
1,956.50
(+1.01%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
